With respect to SOCS7 transcripts, the MS patients treated with GA showed a significant (p = 0.03) increase (1.36 ± 0.23) compared with MS patients treated with IFN-β (0.65 ± 0.10), which suggests that the treatment with GA increases SOCS7 transcription (Figure 2A). This evidence concerns the gene SOCS7 and myeloid sarcoma.